Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0.67
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell